Of these 56/75 ( 74.7 % ) in the linezolid group and 59/75 ( 78.7 % ) in the trimethoprim/sulfamethoxazole and rifampicin group experienced clinical success ( risk difference 4 % , 95 % CI -9.7 % to 17.6 % ) .